The TOPOS study
Safety and efficacy of an oblique common iliac vein stent in patients with post-thrombotic syndrome – two-year results of the TOPOS study
Abstract
Summary:Background: We aimed to study the long-term safety and efficacy of oblique venous stents for post-thrombotic syndrome (PTS) with iliac vein compression. Patients and methods: In the multinational, prospective, single-arm TOPOS study, PTS patients scheduled for endovascular therapy with the sinus-Obliquus® stent and optional distal extension with the sinus-Venous® or sinus-XL Flex® stent were enrolled at eight European vascular centres between October 2016 and December 2020. The primary outcome was primary stent patency at 24 months, and secondary outcomes included the clinical course of PTS (Villalta score, revised Venous Clinical Severity Score [rVCSS], Visual Analog Scale [VAS] of pain), quality of life changes (Chronic Venous Insufficiency Quality of Life Questionnaire, CIVIQ-20), and device-related complications. Results: We enrolled 60 patients (mean age 46±15 years, 68% women, 13% active ulcers): 80% required stent extension (70% below the inguinal ligament). The primary patency rate at 24 months was 80.7% (95%CI 68.1–90.0%); it was higher in patients without vs. those with stent extension (90.9% vs. 78.3%, p=.01). Compared to baseline, the Villalta, rVCSS, pain VAS, and CIVIQ-20 decreased by a median of 8 (interquartile range (IQR): 4–11), 5 (IQR: 3–7), 3 (IQR: 2–5), and 17 (IQR: 6–22) points, respectively; p<.001 for all parameters. Overall, 9 events of acute stent occlusion, 4 symptomatic stent stenosis, and 1 pulmonary embolism occurred. We did not observe major bleeding events or contralateral thrombosis. Conclusions: Endovascular treatment with the oblique stent and optional stent extension was safe and resulted in high patency rates at 24 months. The reduction in PTS severity was substantial and persisted over 2-year follow-up.
References
1 . Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease – A systematic review. Phlebology. 2020;35(4):221–30. https://doi.org/10.1177/0268355519889873
2 Physical properties of venous stents: an experimental comparison. Cardiovasc Intervent Radiol. 2018;41(6):942–50. https://doi.org/10.1007/s00270-018-1916-1
3 Early clinical outcomes for treatment of post-thrombotic syndrome and common iliac vein compression with a hybrid Oblique self-expanding nitinol stent – the TOPOS study. Vasa. 2020;49(4):301–8. https://doi.org/10.1024/0301-1526/a000857
4 Twelve-month clinical outcomes of a hybrid oblique self-expanding nitinol stent used for the treatment of post-thrombotic syndrome with common iliac vein compression: The TOPOS study. Vasc Med. 2021;26(5):569–71. https://doi.org/10.1177/1358863X211017658
5 . Midterm outcomes (2 years) using the VenovoTM and Sinus ObliquusTM venous stents in the treatment of non-thrombotic and post-thrombotic iliac vein lesions – Results from a multi-centre Asian cohort. Phlebology. 2022;37(7):543–7. https://doi.org/10.1177/02683555221094401
6 Use of the VENOVOTM and Sinus ObliquusTM venous stents in the treatment of non-thrombotic or post-thrombotic iliac vein lesions – Short-term results from a multi-centre Asian cohort. Phlebology. 2021;36(1):70–8. https://doi.org/10.1177/0268355520946219
7 . Patency rates, safety and clinical results of the sinus-Obliquus venous stent in the treatment of chronic ilio-femoral venous outflow obstruction – data from the Arnsberg venous registry. Vasa. 2019;48(3):270–5. https://doi.org/10.1024/0301-1526/a000772
8 . Patency and clinical outcomes of a dedicated, self-expanding, hybrid oblique stent used in the treatment of common iliac vein compression. J Endovasc Ther. 2017;24(1):159–66. https://doi.org/10.1177/1526602816676803
9 . Three-year results from the venovo venous stent study for the treatment of iliac and femoral vein obstruction. Cardiovasc Intervent Radiol. 2021;44(12):1918–29. https://doi.org/10.1007/s00270-021-02975-2
10 . Twelve-month end point results from the evaluation of the Zilver Vena venous stent in the treatment of symptomatic iliofemoral venous outflow obstruction (VIVO clinical study). J Vasc Surg Venous Lymphat Disord. 2023; https://doi.org/10.1016/j.jvsv.2022.12.066
11 Pivotal study evaluating the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction. Circ Cardiovasc Interv. 2022;15(2):e010960. https://doi.org/10.1161/circinterventions.121.010960
12 Midterm and long-term outcomes following dedicated endovenous nitinol stent placement for symptomatic iliofemoral venous obstruction: three- to 5-year results of the VIRTUS study. J Vasc Interv Radiol. 2022;33(12):1485–91.e1. https://doi.org/10.1016/j.jvir.2022.08.028
13 . Safety and effectiveness of stent placement for iliofemoral venous outflow obstruction: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015;8(10):e002772. https://doi.org/10.1161/circinterventions.115.002772
14 Self-expandable nitinol stents for the treatment of nonmalignant deep venous obstruction. Circ Cardiovasc Interv. 2020;13(12):e009673. https://doi.org/10.1161/circinterventions.120.009673
15 Incidence of stent thrombosis after endovascular treatment of iliofemoral or caval veins in patients with the postthrombotic syndrome. Thromb Haemost. 2019;119(12):2064–73. https://doi.org/10.1055/s-0039-1697955
16 Venoplasty and stenting in post-thrombotic syndrome and non-thrombotic iliac vein lesion. Minim Invasive Ther Allied Technol. 2020;29(1):35–41. https://doi.org/10.1080/13645706.2019.1580748
17 . The initial report on 1-year outcomes of the feasibility study of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction. J Vasc Surg Venous Lymphat Disord. 2018;6(2):192–200. https://doi.org/10.1016/j.jvsv.2017.10.014